Albert Sabin and prove its extraordinary effectiveness and safety. The Sabin vaccine worked in the intestines to block the poliovirus from entering the bloodstream. In the intestines, Sabin had discovered, the poliovirus multiplied and attacked. Thus, the oral vaccine broke the chain of transmission of the virus and allowed for the possibility that polio might one day be eradicated. Between 1955 and 1961, the oral vaccine was tested on at least 100 million people in the USSR, parts of Eastern Europe, Singapore, Mexico, and the Netherlands. The first industrial production and mass use of oral poliovirus vaccine (OPV) from Sabin strains was
Sabin Vaccine Institute Africa, and the Americas. Sabin is currently working on multiple vaccines for humans including vaccines for Hookworm infection ("Na"-GST-1, "Na"-APR-1), Schistosomiasis ("Sm"-TSP-2), Chagas disease ("Tc"24, TSA-1), Leishmaniasis ("Ld"-NH36, PdSP15), Severe acute respiratory syndrome (SARS)/Middle East respiratory syndrome (MERS) (Pan-β-CoVax), Soil-transmitted helminthiasis (STH), and Onchocerciasis (Ov-"103", Ov-"RAL-2"). In 2006, Sabin co-founded the Global Network for Neglected Tropical Diseases in order "to raise the awareness, political will and funding necessary to control and eliminate the most common NTDs." Through its work on NTDs, Sabin hopes to reduce poverty caused by these diseases as many of them have been shown to adversely affect